Dysfunctional antigen-specific CD8+ T cells in the tumor microenvironment
US11566077B2 · kind B2 · utility
0Cited by
3References
13Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jan 17, 2018 |
| Grant date | Jan 31, 2023 |
| Priority date | — |
| Expiry date | Feb 4, 2038 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/76
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided herein are compositions and methods for detecting and/or targeting dysfunctional tumor antigen-specific CD8+ T cells in the tumor microenvironment for diagnostic, therapeutic and/or research applications. In particular, dysfunctional tumor antigen-specific CD8+ T cells are detected and/or targeted via their expression of cell surface receptors described herein, such as 4-1BB, LAG-3, or additional markers that correlate with 4-1BB and LAG-3 expression, such as markers differentially expressed on the surface of the T cells.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.